NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study

  • NeuroSense Therapeutics Ltd NRSN has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD).
  • Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating PrimeC.
  • Preliminary results showed that levels of disease-related biomarkers in people with ALS were unchanged, in contrast to a statistically significant decline in biomarkers when PrimeC was administered.
  • NeuroSense's biomarker study indicates that CogniC's mechanism of action may effectively target the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy. 
  • Additionally, hallmarks of AD were detected, such as increased levels of amyloid-β (Aβ) and intracellular aggregates of tau protein among the panel of biomarkers evaluated.
  • Preliminary results revealed high levels of TDP-43 in people who suffer from AD compared to the healthy control group. 
  • NeuroSense says that CogniC has already been shown to impact TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis (ALS).
  • NeuroSense is conducting its AD biomarker study using Neuron-Derived Exosomes to observe key alterations in biomarkers. 
  • Price Action: NRSN shares are up 62.4% at $4.45 during the premarket session on the last check Thursday.

Posted In: Briefswhy it's movingBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.